242 related articles for article (PubMed ID: 25724527)
61. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
Powderly J; Spira A; Kondo S; Doi T; Luke JJ; Rasco D; Gao B; Tanner M; Cassier PA; Gazzah A; Italiano A; Tosi D; Afar DE; Parikh A; Engelhardt B; Englert S; Lambert SL; Kasichayanula S; Mensing S; Menon R; Vosganian G; Tolcher A
Clin Transl Sci; 2021 Jan; 14(1):277-287. PubMed ID: 32770720
[TBL] [Abstract][Full Text] [Related]
62. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.
Desai J; Deva S; Lee JS; Lin CC; Yen CJ; Chao Y; Keam B; Jameson M; Hou MM; Kang YK; Markman B; Lu CH; Rau KM; Lee KH; Horvath L; Friedlander M; Hill A; Sandhu S; Barlow P; Wu CY; Zhang Y; Liang L; Wu J; Paton V; Millward M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32540858
[TBL] [Abstract][Full Text] [Related]
63. Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors.
Murakami H; Doi T; Yamamoto N; Watanabe J; Boku N; Fuse N; Yoshino T; Ohtsu A; Otani S; Shibayama K; Takubo T; Loh E
Cancer Chemother Pharmacol; 2012 Sep; 70(3):407-14. PubMed ID: 22810805
[TBL] [Abstract][Full Text] [Related]
64. A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors.
Jhaveri K; Miller K; Rosen L; Schneider B; Chap L; Hannah A; Zhong Z; Ma W; Hudis C; Modi S
Clin Cancer Res; 2012 Sep; 18(18):5090-8. PubMed ID: 22781552
[TBL] [Abstract][Full Text] [Related]
65. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
66. First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors.
Menke-van der Houven van Oordt CW; Gomez-Roca C; van Herpen C; Coveler AL; Mahalingam D; Verheul HM; van der Graaf WT; Christen R; Rüttinger D; Weigand S; Cannarile MA; Heil F; Brewster M; Walz AC; Nayak TK; Guarin E; Meresse V; Le Tourneau C
Oncotarget; 2016 Nov; 7(48):80046-80058. PubMed ID: 27507056
[TBL] [Abstract][Full Text] [Related]
67. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
Kim TW; Bedard PL; LoRusso P; Gordon MS; Bendell J; Oh DY; Ahn MJ; Garralda E; D'Angelo SP; Desai J; Hodi FS; Wainberg Z; Delord JP; Cassier PA; Cervantes A; Gil-Martin M; Wu B; Patil NS; Jin Y; Hoang T; Mendus D; Wen X; Meng R; Cho BC
JAMA Oncol; 2023 Nov; 9(11):1574-1582. PubMed ID: 37768658
[TBL] [Abstract][Full Text] [Related]
68. A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors.
Chiorean EG; Sweeney C; Youssoufian H; Qin A; Dontabhaktuni A; Loizos N; Nippgen J; Amato R
Cancer Chemother Pharmacol; 2014 Mar; 73(3):595-604. PubMed ID: 24452395
[TBL] [Abstract][Full Text] [Related]
69. Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors.
LoRusso P; Jänne PA; Oliveira M; Rizvi N; Malburg L; Keedy V; Yee L; Copigneaux C; Hettmann T; Wu CY; Ang A; Halim AB; Beckman RA; Beaupre D; Berlin J
Clin Cancer Res; 2013 Jun; 19(11):3078-87. PubMed ID: 23591447
[TBL] [Abstract][Full Text] [Related]
70. First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors.
Shapiro GI; Vaishampayan UN; LoRusso P; Barton J; Hua S; Reich SD; Shazer R; Taylor CT; Xuan D; Borghaei H
Invest New Drugs; 2017 Jun; 35(3):315-323. PubMed ID: 28070718
[TBL] [Abstract][Full Text] [Related]
71. Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors.
Fujiwara Y; Iguchi H; Yamamoto N; Hayama M; Nii M; Ueda S; Komuro K; Sugimoto M; Vlahovic G; Kozuki T
Cancer Sci; 2019 May; 110(5):1715-1723. PubMed ID: 30891877
[TBL] [Abstract][Full Text] [Related]
72. Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors.
Yamamoto N; Koyama T; Shimizu T; Todaka A; Kawakami T; Erzen D; Sarashina A; Li B; Hou J; Yamazaki K
Cancer Chemother Pharmacol; 2023 Jun; 91(6):469-480. PubMed ID: 37140602
[TBL] [Abstract][Full Text] [Related]
73. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.
Kyriakopoulos CE; Braden AM; Kolesar JM; Eickhoff JC; Bailey HH; Heideman J; Liu G; Wisinski KB
Invest New Drugs; 2017 Jun; 35(3):290-297. PubMed ID: 28004284
[TBL] [Abstract][Full Text] [Related]
74. A phase 1 study of ABT-806 in subjects with advanced solid tumors.
Cleary JM; Reardon DA; Azad N; Gandhi L; Shapiro GI; Chaves J; Pedersen M; Ansell P; Ames W; Xiong H; Munasinghe W; Dudley M; Reilly EB; Holen K; Humerickhouse R
Invest New Drugs; 2015 Jun; 33(3):671-8. PubMed ID: 25895099
[TBL] [Abstract][Full Text] [Related]
75. A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
Shapiro GI; LoRusso P; Cho DC; Musib L; Yan Y; Wongchenko M; Chang I; Patel P; Chan IT; Sanabria-Bohorquez S; Meng RD; Bendell JC
Invest New Drugs; 2021 Feb; 39(1):163-174. PubMed ID: 32737717
[TBL] [Abstract][Full Text] [Related]
76. Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.
Shah MH; Lorigan P; O'Brien ME; Fossella FV; Moore KN; Bhatia S; Kirby M; Woll PJ
Invest New Drugs; 2016 Jun; 34(3):290-9. PubMed ID: 26961907
[TBL] [Abstract][Full Text] [Related]
77. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.
Patnaik A; Kang SP; Rasco D; Papadopoulos KP; Elassaiss-Schaap J; Beeram M; Drengler R; Chen C; Smith L; Espino G; Gergich K; Delgado L; Daud A; Lindia JA; Li XN; Pierce RH; Yearley JH; Wu D; Laterza O; Lehnert M; Iannone R; Tolcher AW
Clin Cancer Res; 2015 Oct; 21(19):4286-93. PubMed ID: 25977344
[TBL] [Abstract][Full Text] [Related]
78. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.
Angevin E; Tabernero J; Elez E; Cohen SJ; Bahleda R; van Laethem JL; Ottensmeier C; Lopez-Martin JA; Clive S; Joly F; Ray-Coquard I; Dirix L; Machiels JP; Steven N; Reddy M; Hall B; Puchalski TA; Bandekar R; van de Velde H; Tromp B; Vermeulen J; Kurzrock R
Clin Cancer Res; 2014 Apr; 20(8):2192-204. PubMed ID: 24563479
[TBL] [Abstract][Full Text] [Related]
79. First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors.
Zhao Y; Ma Y; Zang A; Cheng Y; Zhang Y; Wang X; Chen Z; Qu S; He J; Chen C; Jin C; Zhu D; Li Q; Liu X; Su W; Ba Y; Hao Y; Chen J; Zhang G; Qu S; Li Y; Feng W; Yang M; Liu B; Ouyang W; Liang J; Yu Z; Kang X; Xue S; Yang G; Yan W; Yang Y; Liu Z; Peng Y; Fanslow B; Huang X; Zhang L; Zhao H
J Hematol Oncol; 2023 May; 16(1):50. PubMed ID: 37158938
[TBL] [Abstract][Full Text] [Related]
80. First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.
Kim TW; Burris HA; de Miguel Luken MJ; Pishvaian MJ; Bang YJ; Gordon M; Awada A; Camidge DR; Hodi FS; McArthur GA; Miller WH; Cervantes A; Chow LQ; Lesokhin AM; Rutten A; Sznol M; Rishipathak D; Chen SC; Stefanich E; Pourmohamad T; Anderson M; Kim J; Huseni M; Rhee I; Siu LL
Clin Cancer Res; 2022 Aug; 28(16):3452-3463. PubMed ID: 35699599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
